Trials / Completed
CompletedNCT04397107
The Therapeutic Value and Mechanism of Recombinant Human Interleukin-2 on Children With Rheumatic Diseases
The Therapeutic Value and Mechanism of Recombinant Human Interleukin-2 on Children With Rheumatic Diseases (Systemic Lupus Erythematosus, Primary Sjögren Syndrome, Juvenile Idiopathic Arthritis)
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 46 (actual)
- Sponsor
- The First Hospital of Jilin University · Academic / Other
- Sex
- All
- Age
- 17 Years
- Healthy volunteers
- Accepted
Summary
The study aims to explore the therapeutic value and mechanism of Interleukin-2 on children with rheumatic diseases (Systemic Lupus Erythematosus, Primary Sjögren Syndrome, Juvenile Idiopathic Arthritis).
Detailed description
The investigators designed a single center, open-label, prospective study that routinely administered low-dose IL-2 therapy to monitor the improvement of clinical and laboratory parameters to explore its efficacy and to observe changes in immune cell subsets and cytokines. Methods: Patients were divided into two groups. One received standard therapy, while another one administrate with low-does IL-2 plus standard therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | IL-2 | Patients were received low dose recombinant human Interleukin-2 |
Timeline
- Start date
- 2020-08-15
- Primary completion
- 2022-05-31
- Completion
- 2022-06-30
- First posted
- 2020-05-21
- Last updated
- 2022-08-18
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04397107. Inclusion in this directory is not an endorsement.